Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01005745 · ClinicalTrials.gov registry record · NA
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
A NA study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- NA
- Development phase
- 19
- Enrollment target
NCT01005745 is a NA study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 19 participants.
The verdict
NCT01005745, a NA study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 19 participants
- Enrollment target
Study Summary
The overall purpose of this research study is to find a better way to treat melanoma. This will be a single arm exploratory trial to evaluate prospectively the feasibility of, the toxicities of, and the persistence of TIL which can survive in vivo.
Interventions
- PROCEDURE Surgery
- DRUG Administration of Lymphodepletion
- OTHER Adoptive Cell Transfer
- DRUG High Dose IL-2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2009-10-20 |
| Est. Completion | 2025-08-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01005745
The ClinicalTrials.gov registry entry for NCT01005745 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Surgery is the first listed.
NCT01005745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01005745 about?
NCT01005745 is a clinical study titled "Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma". The overall purpose of this research study is to find a better way to treat melanoma. This will be a single arm exploratory trial to evaluate prospectively the feasibility of, the toxicities of, and the persistence of TIL which can survive in vivo.
What is the current status of trial NCT01005745?
This trial is currently completed. It is a NA study. The enrollment target is 19 participants. The study started on 2009-10-20. Estimated completion is 2025-08-18.
What interventions are being tested in trial NCT01005745?
The interventions under investigation include: Surgery (PROCEDURE), Administration of Lymphodepletion (DRUG), Adoptive Cell Transfer (OTHER), High Dose IL-2 (DRUG).
Who is sponsoring clinical trial NCT01005745?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.